LOS ANGELES, CA -- (Marketwired) -- 05/09/17 -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or…
Continue ReadingTag: rp-g28
Ritter Pharmaceuticals, Inc. Announces End of Phase 2 Meeting with the FDA and Initiates Phase 3 Program Development Activities
LOS ANGELES, CA -- (Marketwired) -- 04/12/17 -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (the "Company") today,…
Continue ReadingRitter Pharmaceuticals Announces Lactose Intolerance Treatment, RP-G28, Demonstrated Efficacy and Clinically Meaningful Benefit in Phase 2b/3 Clinical Trial
LOS ANGELES, CA -- (Marketwired) -- 03/28/17 -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR)Data Supports Further Clinical…
Continue ReadingRitter Pharmaceuticals Announces Collaboration with University of British Columbia to Explore Development of Microbiome Therapeutics in Environmental Enteropathy
LOS ANGELES, CA -- (Marketwired) -- 02/13/17 -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or…
Continue ReadingRitter Pharmaceuticals to Ring Today–s Nasdaq Stock Market Closing Bell to Kick-off Lactose Intolerance Awareness Month
LOS ANGELES, CA -- (Marketwired) -- 01/30/17 -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or…
Continue Reading